BBP – Virtus LifeSci Biotech Products ETF
Virtus LifeSci Biotech Products ETF (BBP) is a Health ETF, issued by Virtus, $46.1M in assets, 0.79% expense ratio.
Returns as of Oct 23, 2026: 1 week +1.9%, 1 year +36.3%.
Tracks U.S. exchange-listed biotech companies with at least one FDA-approved drug therapy for marketing.
Top holdings
- NK – NantKwest Inc, 3.6%
- DVAX – Dynavax Technologies Corporation, 2.2%
- MRNA – Moderna Inc, 2.2%
- MIRM – Mirum Pharmaceuticals Inc, 2.2%
- FOLD – Amicus Therapeutics Inc, 2.1%
- NVAX – Novavax Inc, 1.9%
- DAWN – Day One Biopharmaceuticals Inc, 1.9%
- AXSM – Axsome Therapeutics Inc, 1.8%
- KRYS – Krystal Biotech Inc, 1.8%
- BNTX – BioNTech SE, 1.8%
- HALO – Halozyme Therapeutics Inc, 1.8%
- INCY – Incyte Corporation, 1.7%
- CRNX – Crinetics Pharmaceuticals Inc, 1.7%
- TBPH – Theravance Biopharma Inc, 1.7%
- ARDX – Ardelyx Inc, 1.7%
- EXEL – Exelixis Inc, 1.7%
- IOVA – Iovance Biotherapeutics Inc, 1.7%
- BGNE – BeiGene Ltd, 1.6%
- ROIV – Roivant Sciences Ltd, 1.6%
- ZLAB – Zai Lab Ltd, 1.6%
- AMGN – Amgen Inc, 1.6%
- GILD – Gilead Sciences Inc, 1.6%
- BMRN – Biomarin Pharmaceutical Inc, 1.6%
- LGND – Ligand Pharmaceuticals Incorporated, 1.6%
- BBIO – BridgeBio Pharma Inc, 1.6%